Research Square

Preprints are preliminary reports that have not undergone peer review.
They should not be considered conclusive, used to inform clinical practice,
or referenced by the media as validated information.

Evaluation of antibiotic resistance in Salmonella spp. isolated from clinical samples in Niamey, Niger

Alio Mahamadou Fody
juniorfodym@gmail.com
University Abdou Moumouni of Niamey
Chaibou Yaou
Abdou Moumouni University
Hadiza Ibrahim Bawa
University Joseph KI-ZERBO of Ouagadougou
Laouali Boubou
Bacteriology Laboratory of Niamey National Hospital (NNH)
Mohamed Alassane Halawen
Microbiology Laboratory of the General Reference Hospital (GRH)
Ramatou Sidikou
Abdou Moumouni University
Hassimi Sadou
Abdou Moumouni University
Nicolas Barro
University Joseph KI-ZERBO of Ouagadougou

Research Article

Keywords: Salmonella spp., clinical isolates, antimicrobial resistance, multidrug resistance, extended-spectrum beta-lactamases (ESBL), Niger

Posted Date: November 5th, 2025

DOI: https://doi.org/10.21203/rs.3.rs-7382210/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Additional Declarations: No competing interests reported.

Abstract

Background: *Salmonella* spp. are leading causes of gastroenteritis and typhoid fever worldwide, with hospital-acquired infections posing significant clinical challenges. The emergence of antibiotic resistance among clinical isolates has been increasingly recognized as a major contributor to treatment failure in affected patients. This study aimed to determine the prevalence and antimicrobial resistance patterns of *Salmonella* spp. isolated from clinical specimens at the National Hospital of Niamey, Niger.

Results: A total of 3,024 stool and blood samples were collected from patients presenting with clinical signs of enteric fever or gastroenteritis. *Salmonella* spp. was identified via standard microbiological methods, and antimicrobial susceptibility testing was performed via the disk diffusion method on Mueller−Hinton agar in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines. Extended-spectrum beta-lactamase (ESBL) production was confirmed by a double-disk synergy test, which assessed theenhancement of inhibition zones between amoxicillin/clavulanic acid and third-generation cephalosporins.

Seventy-seven *Salmonella*isolates were recovered, yielding an overall prevalence of 2.55%. The majority of the isolates (80.52%) were obtained from children under 5 years of age. High resistance rates were observed against amoxicillin and amoxicillin/clavulanic acid (79% each). Multidrug resistance (resistance to ≥3 antibiotic classes) was detected in 25.97% of the isolates, whereas 35% were resistant to at least two antibiotics. Notably, 5.19% of the isolates were confirmed as ESBL-producing strains.

Conclusion: These findings highlight the significant burden of multidrug-resistant *Salmonella* spp., including ESBL producers, in the clinical setting of Niamey. The high prevalence of resistance to commonly used antibiotics underscores the urgent need for enhanced antimicrobial resistance surveillance, rational antibiotic use, and infection control strategies to curb the spread of resistant strains in healthcare and community environments.

Background

Salmonella is a gram-negative, zoonotic enteric bacterium responsible for a significant burden of foodborne illness in both humans and animals worldwide [1,2]. The genus encompasses a diverse group of pathogens that collectively account for an estimated 93.8 million annual cases of gastroenteritis worldwide, resulting in approximately 155,000 deaths [3]. Additionally, *Salmonella enterica* serovars Typhi and Paratyphi are the causative agents of enteric fever, contributing to 11–21 million cases of typhoid fever and 128,000–161,000 associated deaths annually, as well as an estimated 6 million cases of paratyphoid fever, with over 54,000 fatalities [4]. In sub-Saharan Africa, nontyphoidal

Salmonella infections are a major cause of invasive bacterial disease, contributing to approximately 680,000 deaths each year [5].

The emergence and spread of antimicrobial resistance (AMR) in *Salmonella* spp. represent critical public health challenges. Resistance to first- and second-line antibiotics compromises the efficacy of clinical treatment, leading to prolonged illness, increased risk of complications, and increased mortality rates [2]. In sub-Saharan West Africa, the mortality burden attributable to AMR is particularly high, with estimates reaching 27.3 deaths per 100,000 infections [6]. Furthermore, the World Bank projects that AMR could increase healthcare expenditures by up to 25% in low-income countries and by 8% globally [7].

Multidrug-resistant (MDR) *Salmonella* strains have been increasingly reported during outbreaks, undermining therapeutic options for salmonellosis [8]. In Burkina Faso, MDR phenotypes are increasing among *Salmonella* isolates from pediatric populations [9], whereas in Niger, recent studies have documented the emergence of resistance to third-generation cephalosporins and fluoroquinolone key agents used in the management of invasive salmonellosis and shigellosis, highlighting the need for cautious antibiotic use and continuous surveillance [10].

This study aimed to evaluate the antimicrobial susceptibility profiles of *Salmonella* spp. isolated from blood and stool samples at the National Hospital of Niamey, Niger. These findings provide critical insights into the current patterns of resistance to antibiotics commonly employed in the treatment of gastroenteritis and enteric fever, informing clinical decision-making and public health interventions in the region.

Methods

Study Design and Duration

A descriptive cross-sectional study was conducted between July 2017 and May 2018 at the Laboratory of Clinical Biology, National Hospital of Niamey. Stool and blood samples were collected from patients who presented with diarrhea or clinically suspected typhoid fever.

Sample collection and culture procedures

Stool samples

Stool samples were collected aseptically in sterile containers. Approximately one gram of each sample was suspended in physiological saline for preenrichment. A few drops of the suspension were subsequently inoculated into selenite broth and incubated at 37°C for 10

hours for selective enrichment. Following enrichment, the cultures were streaked onto Hektoen enteric agar and incubated at 37°C for 24 hours for isolation of *Salmonella* species.

Blood samples

Blood samples were collected directly into aerobic blood culture bottles and incubated in the bioMérieux Bact/Alert 3D automated culture system at 37°C for up to 14 days. Bottles flagged as positive by the system were subcultured by inoculating 10 µL onto Hektoen enteric agar, followed by incubation at 37°C for 24 hours.

Identification of Isolates

Suspected *Salmonella* colonies were identified on the basis of their morphological characteristics on selective media, cultural properties, and standard biochemical tests, including oxidase assays (negative for *Salmonella*). Presumptive isolates were further confirmed via the API 20E system (bioMérieux), a standardized, miniaturized panel of 20 biochemical tests designed for the identification of *Enterobacteriaceae* and other gram-negative bacilli. Identification was achieved through numerical code generation and comparison with the reference database.

Antibiotic susceptibility testing

Antibiotic susceptibility was assessed via the disk diffusion method on Mueller−Hinton agar (Liofilchem, Italy) in accordance with the guidelines of the *Comité de l'Antibiogramme de la Société Française de Microbiologie* (CA-SFM) [11]. The tests included antibiotics from three major classes: beta-lactams (amoxicillin [20 µg], amoxicillin-clavulanic acid [20 µg + 10 µg], ceftriaxone [30 µg], ceftazidime [10 µg], cefotaxime [5 µg], and imipenem [10 µg]), aminoglycosides (gentamicin [10 µg] and amikacin [30 µg]), and quinolones (nalidixic acid [30 µg] and ciprofloxacin [5 µg]).

Phenotypic detection of extended-spectrum beta-lactamase (ESBL) production was performed via the double-disk synergy test (DDST), with ceftriaxone (30 µg) and cefotaxime (5 µg) disks placed at a distance of 20 mm (edge-to-edge) from an amoxicillin−clavulanic acid (30 µg) disk, as recommended by the CA-SFM 2017 guidelines [11]. A positive result was defined as an increase in the inhibition zone toward the clavulanic acid disk, indicating synergy.

Ethical considerations

All isolates were derived from biological specimens collected during routine clinical procedures from patients, with ethical approval granted by the Ethics Committee of the National Hospital of Niamey (Authorization No. 00075/DHNN/DAF/SGRH, dated November 15, 2016). No additional sampling was performed for research purposes.

Statistical analysis

The data were entered and analyzed via Microsoft Excel (Microsoft® Office 2019). The chi-square test was used to evaluate associations between categorical variables. A p value < 0.05 was considered statistically significant.

Results

A total of 3,024 clinical specimens, comprising 2,837 stool samples and 187 blood culture samples, were analyzed at the Bacteriology Unit of the National Hospital of Niamey during the study period.

Prevalence of Salmonella spp. by sample type

Overall, 77 *Salmonella* spp. isolates were identified, resulting in a total prevalence of 2.55% (95% CI: 2.02–3.17%). The distribution of *Salmonella* isolates by specimen type is summarized in Table 1.

Among the stool samples, 67 out of 2,837 tested positive for *Salmonella* spp., yielding a prevalence of 2.22% (95% CI: 1.73–2.81%). Among the blood cultures, 10 out of the 187 samples were positive, corresponding to a prevalence of 5.35% (95% CI: 2.68–9.42%). This difference in prevalence between stool and blood samples was statistically significant ($\chi^2 = 13.78$, $p < 0.001$), indicating that a greater proportion of *Salmonella* was detected in blood cultures despite the smaller sample size.

The observed disparity suggests a greater clinical severity associated with bacteremic *Salmonella* infections in this population, although the lower number of blood samples limits direct comparison. These findings highlight the importance of blood culture surveillance in the diagnosis of invasive salmonellosis.

Table 1
Prevalence of *Salmonella spp*. by sample type.

Sample types	Sample numbers	*Salmonella* spp. prevalence % (n)
Stool samples	2,837	2.22 (60)
Blood samples	187	5.35 (10)
Total	**3,024**	**2.55 (77)**

Prevalence of Salmonella spp. strains according to sociodemographic characteristics

As shown in Table 2, the prevalence of *Salmonella* spp. was 53.24% (n = 41) among male patients and 46.76% (n = 36) among female patients. Statistical analysis revealed no significant difference in *the* prevalence of Salmonella between the sexes ($p = 0.5485$).

Salmonellosis affects individuals across all age groups; however, a marked variation in prevalence was observed according to age. The highest prevalence was recorded in children aged 0–5 years, with 80.52% (n = 62) of the cases. In contrast, the prevalence was substantially lower in the older age groups: 3.90% (n = 3) in the 6–18 years group, 7.79% (n = 6) in the 19–25 years group, 2.60% (n = 2) in the 26–45 years group, and 5.19% (n = 4) in the 46–60 years group. This age-related difference in *Salmonella* spp. prevalence was statistically significant ($p < 0.0001$).

Table 2
Prevalence of *Salmonella* spp. by demographic characteristics

Demographic characteristics	*Salmonella spp*. prevalence % (n)
Gender	
Male	53.24 (41)
Female	46.76 (36)
Age (years)	
0–5	80.52 (62)
6–18	3.90 (3)
19–25	7.79 (6)
26–45	2.60 (2)
46–60	5.19 (4)

Prevalence of Salmonella spp. isolates by sample origin

Analysis of the data presented in Table 3 revealed a Salmonella spp. prevalence of 40.26% among outpatients, which was significantly higher ($p < 0.0001$) than that among inpatients across hospitalization departments. Among inpatient clinics, the highest prevalence was observed in the pediatric referral clinic (31.17%), followed by the Pediatrics A clinic (23.38%). Lower prevalence rates were recorded in the Medicine B clinic (3.90%) and the Pediatrics B clinic (1.30%). A statistically significant variation in Salmonella spp. prevalence was also observed across different hospitalization departments ($p < 0.0001$).

Table 3
Prevalence of *Salmonella* spp. isolates according to sample origin.

Samples origin	*Salmonella spp.* prevalence % (n)
Pediatrics A office	23.38 (18)
Pediatrics B office	1.30 (1)
Pediatric referral office	31.17 (24)
Medicine B office	3.90 (3)
External	40.26 (31)

Antibiotic susceptibility of Salmonella spp. isolates

Analysis of *Salmonella* spp. isolates obtained from blood cultures (Fig. 1) revealed high resistance rates within the beta-lactam antibiotic class: 90% of the isolates were resistant to both amoxicillin and amoxicillin/clavulanic acid. In contrast, susceptibility to third-generation cephalosporins was high, with 90% of the isolates showing sensitivity to ceftazidime, cefotaxime, and ceftriaxone. All the isolates were fully susceptible (100% sensitivity) to the carbapenem imipenem. Among the 10 antibiotics tested, only a single isolate exhibited multidrug resistance, defined as resistance to eight antimicrobial agents.

With respect to aminoglycosides, 90% of the isolates were susceptible to gentamicin, whereas 100% were susceptible to amikacin. Within the quinolone class, both nalidixic acid and ciprofloxacin demonstrated 90% susceptibility rates.

These findings highlight a high level of resistance to certain beta-lactams but preserved susceptibility to extended-spectrum cephalosporins, carbapenems, aminoglycosides, and fluoroquinolones among the majority of *Salmonella* spp. isolates.

Analysis of stool-derived bacterial isolates (Fig. 2) revealed antimicrobial susceptibility patterns across key antibiotic classes. Among β-lactam agents, amoxicillin and amoxicillin-clavulanate (augmentin) have low susceptibility rates, with a reported sensitivity of 31%. In contrast, extended-spectrum cephalosporins and carbapenems demonstrated greater efficacy: ceftazidime had 60% sensitivity, cefotaxime had 67%, ceftriaxone had 70%, and imipenem had a markedly high sensitivity rate of 99%.

Within the aminoglycoside class, the susceptibility rates were 64% for gentamicin and 94% for amikacin, indicating the superior activity of the latter.

Specifically, among *Salmonella* spp. isolates, susceptibility to nalidixic acid was 73%, whereas 75% of isolates were susceptible to amikacin.

These findings highlight high resistance to penicillins, variable sensitivity to cephalosporins, and preserved susceptibility to carbapenems and amikacin, suggesting that these agents may remain effective therapeutic options in the management of infections caused by these enteric pathogens.

Prevalence of multidrug-resistant Salmonella spp. strains

Analysis of the data presented in Table 4 revealed that 20.78% of the *Salmonella* spp. isolates were susceptible to all antibiotics tested in this study. In contrast, only a single isolate (1.30%), obtained from a stool sample, exhibited resistance to all the tested antimicrobial agents. Resistance to nine, eight, seven, six, and five antibiotics was observed in 2.60%, 12.99%, 3.90%, 3.90%, and 1.30% of the isolates, respectively. Notably, a substantial proportion of the isolates (35.06%) displayed resistance to two antibiotics, indicating a high prevalence of multidrug resistance among the *Salmonella* strains analyzed.

Table 4
Prevalence of multidrug-resistant Salmonella spp.

Number of resistant antibiotics	Resistance of Salmonella spp % (n)
10	1.30 (1)
9	2.60 (2)
8	12.99 (10)
7	3.90 (3)
6	3.90 (3)
5	1.30 (1)
4	2.60 (2)
3	9.09 (7)
2	35.06 (27)
1	6.49 (5)

Prevalence of extended-spectrum beta-lactamase (ESBL)-producing Salmonella spp.

An analysis of the data in Table 5 revealed that 20 *Salmonella* spp. isolates were resistant to at least five antibiotics, resulting in a multidrug resistance prevalence of 25.97%. Among these multidrug-resistant isolates, four were identified as extended-spectrum beta-lactamase (ESBL) producers and were isolated from stool samples. This corresponds to an overall prevalence of 5.19% for ESBL-producing *Salmonella* spp. (Table 5).

Table 5
Prevalence of ESBL-producing *Salmonella* spp.

Samples types	Multiresistant *Salmonella* spp.	*Salmonella* spp. BLSE
Stool samples	24.67% (19)	5.19% (4)
Blood samples	1.30% (1)	0.00% (0)
Total	25.97% (20)	5.19% (4)

Discussion

Salmonella infections represent a significant public health burden in Africa, particularly among poor urban populations, where they contribute to a disproportionate number of deaths [12]. This burden is exacerbated in low-income countries because of inadequate control measures and limited adherence to proper food safety practices [13].

In this study, the prevalence of *Salmonella* spp. in clinical stool samples was 2.22%. This finding is comparable to reports from Burkina Faso (3.07%) and Nepal (3.1%) ($p = 0.6547$) [14,15]. However, it is significantly lower than the prevalence reported in other studies conducted in Burkina Faso (9.50%), Tanzania (16.5%), and Iraq (14.8%) ($p = 0.0068$) [9,16,17]. These discrepancies may be attributed to differences in study design, sample size, population characteristics, and regional variations in hygiene, sanitation, and healthcare access.

Notably, a low prevalence of 0.33% was observed in the blood culture samples. This result is significantly lower ($p < 0.0001$) than those reported in studies from the Democratic Republic of the Congo (41.66%), Nigeria (7.27%), Kenya (3.54%), and Nepal (3.10%) [18–21]. The low bacteremia rate in our study may be partly explained by the relatively short duration of the study period and the limited sample size, which could affect the detection of bloodstream infections.

With respect to sex distribution, *Salmonella* spp. were more frequently isolated from male patients (53.24%) than from female patients (46.76%). This observation aligns with findings from studies in Mali [24] and Tanzania [25]. The higher prevalence among males may be associated with behavioral and socioeconomic factors, such as a greater frequency of eating outside the home, potentially increasing exposure to contaminated food or water sources.

Children aged 0–5 years presented the highest prevalence of *Salmonella* spp. infection (80.52%). This finding is consistent with data from Iran, where a high incidence was reported in children under 4 years of age [26], and from Bangladesh, where 62% of typhoid fever cases were attributed to *Salmonella* spp. [27]. The heightened susceptibility

of young children may be linked to widespread malnutrition in resource-limited settings, which can compromise intestinal immunity and alter the gut microbiota, thereby increasing vulnerability to enteric pathogens [28].

Antimicrobial susceptibility testing revealed high levels of resistance to amoxicillin and amoxicillin/clavulanic acid. These findings are consistent with a study in Nigeria, which reported 100% resistance to amoxicillin/clavulanic acid [19]. In contrast, studies in Kathmandu and Nepal demonstrated high sensitivity (91% and 100%, respectively) to amoxicillin [20,21]. The observed variation in resistance patterns may reflect differences in antibiotic usage practices, including widespread self-medication for symptoms such as fever, diarrhea, and respiratory infections, as well as the empirical prescription of antibiotics without microbiological confirmation or susceptibility testing [27].

Resistance to third-generation cephalosporins—ceftazidime, cefotaxime, and ceftriaxone—was low in our isolates. These results are in agreement with previous reports from Nepal [21] and Niger [10]. However, a study in Nigeria reported 100% resistance to ceftazidime and cefotaxime [19], which may be attributed to prior antibiotic exposure, as the isolates in that study were obtained from patients already experiencing febrile illness, likely after self-treatment.

Our isolates showed high susceptibility to amikacin (97%) and imipenem (99%), indicating that these agents remain effective therapeutic options for severe salmonellosis. A study in Cameroon reported 90% susceptibility to imipenem [23]; the slightly lower sensitivity may reflect greater carbapenem use in that setting, potentially driving selective pressure.

Multidrug resistance (MDR), defined as resistance to two or more antibiotic classes, was observed in 35% of *Salmonella* spp. isolates. This is lower than the 85% MDR prevalence reported in a Bangladeshi study based on blood isolates [27], a difference that may be influenced by variations in sample size and patient population. Notably, 13% of the isolates in our study exhibited resistance to at least eight different antibiotics, meeting the criteria for extensive drug resistance. This finding is concerning and aligns with reports from South Africa, Mali, and Ethiopia, where 22% of isolates were resistant to three or more antibiotics, 31% to five antibiotics, and 59% to three different antibiotic classes [29–31]. These data underscore a growing trend of increasing antimicrobial resistance among clinical *Salmonella* strains.

Among the MDR isolates, 4 (5.19%) were confirmed as extended-spectrum beta-lactamase (ESBL)-producing strains. This prevalence is comparable to reports from Canada (2%) and Thailand (5.1%) [31,32] but lower than rates reported in Nigeria (40.7%) and Qatar (10%) among patients with confirmed typhoid fever [33,34]. The higher ESBL rates in the latter studies may reflect the clinical context—specifically, that isolates were obtained from

patients with established enteric fever who had likely received prior antimicrobial treatment, thereby selecting for resistant strains.

In conclusion, our findings highlight the persistent burden of *Salmonella* infections, particularly among young children and males, and underscore the growing challenge of antimicrobial resistance. Continued surveillance, improved diagnostic practices, rational antibiotic use, and public health interventions targeting food and water safety are essential to mitigate the impact of *Salmonella* infections in low-resource settings.

Conclusion

This study, which was conducted over a 10-month period at the National Hospital of Niamey, allowed the isolation and identification of Salmonella spp. strains from clinical stool and blood samples. The results revealed a greater prevalence of Salmonella spp. in stool samples than in blood samples. Most of the isolated Salmonella strains were sensitive to the majority of the tested antibiotics, but some showed resistance to certain drugs. Multiple drug-resistant Salmonella strains have been identified, including some that produce extended-spectrum beta-lactamases (ESBLs). Therefore, it is essential to establish a national surveillance system as soon as possible for ESBL-producing Salmonella strains to help prevent their spread.

Abbreviations

AMR
Antimicrobial Resistance
MDR
Multidrug Resistance
ESBL
Extended-Spectrum Beta-Lactamase
CLSI
Clinical and Laboratory Standards Institute
CA-SFM
Comité de l'Antibiogramme de la Société Française de Microbiologie
DDST
Double-Disk Synergy Test
API 20^{E}
Analytical Profile Index 20 Enterobacteriaceae
SF
Société Française de Microbiologie
EUCAST
European Committee on Antimicrobial Susceptibility Testing

LaBESTA
Laboratoire de Biologie Moléculaire, d’Épidémiologie et de Surveillance des Bactéries et Virus Transmissibles par les Aliments (nom du laboratoire au Burkina Faso)"
NNH
Niamey National Hospital
GRH
General Reference Hospital

Declarations

Acknowledgments

We gratefully acknowledge the entire laboratory team from the Biochemistry and Biology Department at the National Hospital of Niamey, particularly the Bacteriology Unit of the Biology Laboratory, for their technical support and valuable contributions to this study. We also extend our sincere gratitude to Boubou Laouali for his dedicated time and assistance.

Author Contribution declaration

Alio Mahamadou Fody collected the data and drafted the document.
Laouali Boubou contributed to data collection.
Chaibou Yaou, Hadiza Ibrahim Bawa, and Mohamed Alassane Halawen participated in reviewing the document.
Nicolas Barro, Hassimi Sadou, and Ramatou Sidikou provided expert input during the drafting process.

Funding

Not applicable.

Data availability

The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Ethics approval and consent to participate

All isolates were derived from biological specimens collected during routine clinical procedures from patients, with ethical approval granted by the Ethics Committee of the National Hospital of Niamey (Authorization No. 00075/DHNN/DAF/SGRH, dated November 15, 2018). Informed consent was obtained from all participants. For children under 16 years of age, written informed consent and assent were obtained from a parent

or legal guardian accompanying the participant to the hospital. All methods were carried out in accordance with the principles outlined in the Declaration of Helsinki.

Clinical trial number

Not Applicable

Consent for publication

Not Applicable

Competing interests

The authors have not declared any conflict of interests.

Author details

[1] Superior Normal School, University Abdou Moumouni of Niamey, Niamey, Niger

[2]Laboratory of Molecular Biology, Epidemiology and Surveillance of Foodborne Bacteria and Viruses (LaBESTA), University Joseph KI-ZERBO of Ouagadougou, Ouagadougou, Burkina Faso.

[3] Department of Chemistry, Faculty of Sciences and Technology, Abdou Moumouni University, Niamey-Niger

[4]Department of Life and Earth Sciences, University of Ouahigouya, UFR / ST-SVT Ouahigouya, Burkina Faso.

[5]Bacteriology Laboratory of Niamey National Hospital (NNH), Niamey, Niger.

[6]Microbiology Laboratory of the General Reference Hospital (GRH), Niamey, Niger.

[7]Biotechnology Laboratory, Faculty of Science and Technology; Abdou Moumouni University, Niamey, Niger.

References

1. Ghoddusi, A., Nayeri Fasaei, B., Zahraei Salehi, T., & Akbarein, H. Serotype distribution and antimicrobial resistance of *Salmonella* isolates in human, chicken, and cattle in Iran. *Archives of Razi Institute*, 2019; 74(3), 259–266. https://doi.org/10.22092/ari.2018.122351
2. Chaudhari, R., Singh, K., & Kodgire, P. Biochemical and molecular mechanisms of antibiotic resistance in *Salmonella* spp. *Research in Microbiology*, 2023; 174(1–2),

103985. https://doi.org/10.1016/j.resmic.2022.103985

3. Shu-kee, E., Priyia, P., Nurul-Syakima, A. B. M., Hooi-leng, S., Kok-Gang, C., & Learn-Han, L. *Salmonella*: A review on pathogenesis, epidemiology and antibiotic resistance. *Frontiers in Life Science*, 2015; 8(3), 284–293.
4. WHO (World Health Organization). *Typhoid fever and other invasive salmonelloses*. WHO Surveillance Standards, 2018. https://www.who.int/docs/default-source
5. Post, A. S., Diallo, S. N., Guiraud, I., Lompo, P., Tahita, M. C., Maltha, J., & Jacobs, J. Supporting evidence for a human reservoir of invasive non-Typhoidal *Salmonella* from household samples in Burkina Faso. *PLoS Neglected Tropical Diseases*, 2019; 13(10), e0007782. https://doi.org/10.1371/journal.pntd.0007782
6. Murray, C. J., Ikuta, K. S., Sharara, F., Swetschinski, L., Aguilar, G. R., Gray, A., & Tasak, N. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet*, 2022; 399(10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0
7. WHO, FAO, OIE, UN. *Antimicrobial Resistance and the United Nations Sustainable Development Cooperation Framework*. Geneva: WHO, 2021. https://apps.who.int/iris/handle/10665/346794
8. Bonilla-Caballero, M. A., Lozano-Puentes, M. P., Ospina, M. A., & Varón-López, M. First report of multidrug-resistant *Salmonella* Infantis in broiler litter in Tolima, Colombia. *Veterinary World*, 2022; 15(6), 1557–1562. https://doi.org/10.14202/vetworld.2022.1557-1562
9. Konaté, A., Guessennd, N. K., Kouadio, F. K., Dembélé, R., Kagambèga, A., et al. Epidemiology and Resistance Phenotypes of *Salmonella* spp. Strains Responsible for Gastroenteritis in Children Less Than Five Years of Age in Ouagadougou, Burkina Faso. *Archives of Clinical Microbiology*, 2019; 10(2), 90. https://doi.org/10.4172/1989-8756.1000090
10. Illa, M., Diallo, B. A., Sani, O., Bassira, I., Abdoulaye, O., & Eric, A. Antibiotic resistance of *Salmonella* and *Shigella*, isolated from diarrheal children under five years old at the national hospital of Niamey (Niger). *European Journal of Pharmaceutical and Medical Research*, 2022; 9(8), 558–564.
11. Société Française de Microbiologie. Comité de l'Antibiogramme (CA-SFM/EUCAST). *Recommandations V1.0 Mars 2017*. Paris: SFM, 2017. www.sfm-microbiologie.org
12. Kariuki, S., Mbae, C., Onsare, R., Kavai, S. M., Wairimu, C., Ngetich, R., & Dougan, G. Multidrug-resistant nontyphoidal *Salmonella* hotspots as targets for vaccine use in management of infections in endemic settings. *Clinical Infectious Diseases*, 2019; 68(Suppl 1), S10–S16. https://doi.org/10.1093/cid/ciy954
13. Bouda, S. C., Kagambega, A., Bonifait, L., Le Gall, F., Ibrahim, H. B., Bako, E., & Barro, N. Prevalence and Antimicrobial Resistance of *Salmonella enterica* Isolated

from Chicken and Guinea Fowl in Burkina Faso. *International Journal of Microbiology and Biotechnology*, 2019; 4(3), 64–71. https://doi.org/10.11648/j.ijmb.20190403.12

14. Dembélé, R., Konaté, A., Soulama, I., Kagambèga, A., Kaboré, W. A. D., & Cissé, H. Prevalence of Multidrug-resistant *Salmonella enterica* and associated factors among under five children with diarrhea in rural Burkina Faso. *Clinical and Biotechnology Microbiology*, 2018; 3(1), 566–576.
15. Maharjan, A., Dhungel, B., Bastola, A., Thapa Shrestha, U., Adhikari, N., Banjara, M. R., & Rijal, K. R. Antimicrobial susceptibility pattern of *Salmonella* spp. isolated from enteric fever patients in Nepal. *Infectious Disease Reports*, 2021; 13(2), 388–400. https://doi.org/10.3390/idr13020036
16. Ngogo, F. A., Abade, A. M., Rumisha, S. F., Mizinduko, M. M., & Majigo, M. V. Factors associated with *Salmonella* infection in patients with gastrointestinal complaints seeking health care at Regional Hospital in Southern Highland of Tanzania. *BMC Infectious Diseases*, 2020; 20(1), 1–8. https://doi.org/10.1186/s12879-020-05190-0
17. Harb, A., Abraham, S., Rusdi, B., Laird, T., O'dea, M., & Habib, I. Molecular detection and epidemiological features of selected bacterial, viral, and parasitic enteropathogens in stool specimens from children with acute diarrhea in Thi-Qar Governorate, Iraq. *International Journal of Environmental Research and Public Health*, 2019; 16(9), 1573. https://doi.org/10.3390/ijerph16091573
18. Kashosi, T. M., Muhandule, A. B., Mwenebitu, D. L., Mihuhi, N., Mutendela, J. K., & Mubagwa, K. Antibio-résistance des souches de *Salmonella* spp isolées d'hémocultures à Bukavu en RD Congo. *Pan African Medical Journal*, 2018; 29(1), 1–8. https://doi.org/10.11604/pamj.2018.29.1.13087
19. Akinkunmi, F., Ajoseh, S., Fakorede, C., Abegunrin, R., Salami, W., Lawal, A., & Akinyemi, K. Prevalence of *Salmonella* blood-stream infection and antimicrobial resistance in Lagos, Nigeria. *Infection Epidemiology and Microbiology*, 2023; 9(1), 0-0.
20. Bastola, A., Pyakurel, P., Rayamajhi, R. B., Shrestha, S., Thekkur, P., Pandey, B., & Edwards, J. K. High Resistance of *Salmonella* spp. In addition, *Shigella* spp. in Blood and Stool Cultures from the Sukraraj Tropical and Infectious Disease Hospital, Kathmandu, Nepal, 2015–2019. *Tropical Medicine and Infectious Disease*, 2021; 6(2), 59. https://doi.org/10.3390/tropicalmed6020059
21. Maharjan, A., Dhungel, B., Bastola, A., Thapa Shrestha, U., Adhikari, N., Banjara, M. R., & Rijal, K. R. Antimicrobial Susceptibility Pattern of *Salmonella* spp. Isolated from Enteric Fever Patients in Nepal. *Infectious Disease Reports*, 2021; 13(2), 388–400. https://doi.org/10.3390/idr13020036
22. Mina, S. A., Hasan, M. Z., Hossain, A. Z., Barua, A., Mirjada, M. R., & Chowdhury, A. M. A. The prevalence of multidrug-resistant *Salmonella typhi* isolated from blood

sample. *Microbiology Insights*, 2023 ; 16, 11786361221150760. https://doi.org/10.1177/11786361221150760

23. Ndip, R., Awah, L., Ghogomu, S., Cho-Ngwa, F., & Ngemenya, M. Isolation and molecular identification of *Salmonella* with high multidrug resistance to first line typhoid antibiotics in Southwest Cameroon. *Microbes and Infectious Diseases*, 2022; 3(4), 988–997. https://doi.org/10.1016/j.micinf.2022.07.003
24. Diarra, B., Guindo, I., Koné, B., Dembélé, M., Cissé, I., Thiam, S., & Djimde, A. High frequency of antimicrobial resistance in *Salmonella* and *Escherichia coli* causing diarrheal diseases at the Yirimadio community health facility, Mali. *BMC Microbiology*, 2024; 24(1), 35. https://doi.org/10.1186/s12866-024-03199-8
25. Hugho, E. A., Kumburu, H. H., Thomas, K., Lukambagire, A. S., Wadugu, B., Amani, N., & Mmbaga, B. T. High diversity of *Salmonella* spp. from children with diarrhea, food, and environmental sources in Kilimanjaro–Tanzania: one health approach. *Frontiers in Microbiology*, 2024; 14, 1277019. https://doi.org/10.3389/fmicb.2023.1277019
26. Abbasi, E., & Ghaznavi-Rad, E. Quinolone resistant *Salmonella* species isolated from pediatric patients with diarrhea in central Iran. *BMC Gastroenterology*, 2021; 21, 1–6. https://doi.org/10.1186/s12876-021-01700-3
27. Mina, S. A., Hasan, M. Z., Hossain, A. Z., Barua, A., Mirjada, M. R., & Chowdhury, A. M. A. The prevalence of multidrug-resistant *Salmonella typhi* isolated from blood sample. *Microbiology Insights*, 2023; 16, 11786361221150760. https://doi.org/10.1177/11786361221150760
28. Zaki, S. A., & Karande, S. Multidrug-resistant typhoid fever: a review. *Journal of Infection in Developing Countries*, 2011; 5(5), 324–337. https://doi.org/10.3855/jidc.1555
29. Ramatla, T., Khasapane, N. G., Mlangeni, L. N., Mokgokong, P., Ramaili, T., Ndou, R., & Thekisoe, O. Detection of *Salmonella* Pathogenicity Islands and Antimicrobial Resistance Genes in *Salmonella enterica* Serovars Enteritidis and Typhimurium Isolated from Broiler Chickens. *Antibiotics*, 2024; 13(5), 458. https://doi.org/10.3390/antibiotics13050458
30. Amare, A., Eshetie, S., Kasew, D., Amare, A., Abebe, W., & Moges, F. Prevalence of *Salmonella* spp., *Shigella* spp., and intestinal parasites among food handlers working in University of Gondar student's cafeteria, Northwest Ethiopia. *Frontiers in Public Health*, 2024; 12, https://doi.org/10.3389/fpubh.2024.1370338
31. Primeau, C. A., Bharat, A., Janecko, N., Carson, C. A., Mulvey, M., Reid-Smith, R., & Parmley, E. J. Integrated surveillance of extended-spectrum beta-lactamase (ESBL)-producing *Salmonella* and *Escherichia coli* from humans and animal species raised for human consumption in Canada from 2012 to 2017. *Epidemiology and Infection*, 2023; 151, e14. https://doi.org/10.1017/S0950268822001847

32. Saechue, B., Atwill, E. R., & Jeamsripong, S. Occurrence and molecular characteristics of antimicrobial resistance, virulence factors, and extended-spectrum β-lactamase (ESBL) producing *Salmonella enterica* and *Escherichia coli* isolated from the retail produce commodities in Bangkok, Thailand. *Heliyon*, 2024; 10(5), e29345. https://doi.org/10.1016/j.heliyon.2024.e29345
33. Akinyemi, K. O., Al-Khafaji, N. S., Al-Alaq, F. T., Fakorede, C. O., Al-Dahmoshi, H. O., Iwalokun, B. A., & Saki, M. Extended-spectrum beta-lactamases encoding genes among *Salmonella enterica* serovar Typhi isolates in patients with typhoid fever from four academic medical centers in Lagos, Nigeria. *Revista de Investigación Clínica*, 2022; 74(3), 165–171. https://doi.org/10.21814/ric.2022.359
34. Goravey, W., Tsui, C. K., Ali, G. A., Najim, M. S., Shunnar, K., Ibrahim, E. B., & Hadi, H. A. Clinical, phenotypic, and genotypic characteristics of ESBL-producing *Salmonella enterica* bloodstream infections from Qatar. *IJID Regions*, 2024; 11, 100368. https://doi.org/10.1016/j.ijregi.2024.100368

Figures




Figure 1

Antibiotic susceptibility of *Salmonella spp*. isolated from blood samples




Figure 2

Antibiotic susceptibility of *Salmonella spp*. isolated from stool samples